# NeoCOAST-2 (NCT05061550)

> Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05061550
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer
- Interventions: Durvalumab; Oleclumab; Monalizumab; Dato-DXd; AZD0171; Carboplatin; Cisplatin; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin; Carboplatin/Paclitaxel; Volrustomig; Rilvegostomig
- Enrollment: 630
- Primary outcome: Number of participants with pathological complete response (pCR)
- Primary outcome: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

## Commentary we found

- X threads: 46
- YouTube: 11
- Podcasts: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neocoast-2-nct05061550

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05061550", "email": "<work email>"}; the inbox owner confirms by the emailed link.